34. 神経線維腫症 Neurofibromatosis Clinical trials / Disease details


臨床試験数 : 133 薬物数 : 186 - (DrugBank : 67) / 標的遺伝子数 : 79 - 標的パスウェイ数 : 190

  
3 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05028166
(ClinicalTrials.gov)
October 1, 202124/8/2021Individual Patient Compassionate Use of MirdametinibNeurofibromatosis Type 1-Associated Plexiform Neurofibromas;Histiocytic Neoplasm;Other MAP-K Pathway Driven DiseasesDrug: Mirdametinib (MEK Inhibitor)SpringWorks Therapeutics, Inc.NULLAvailable2 YearsN/AAllNULL
2NCT03962543
(ClinicalTrials.gov)
September 6, 201912/4/2019MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform NeurofibromasA Phase 2b Trial of the MEK 1/2 Inhibitor (MEKi) PD-0325901 in Adult and Pediatric Patients With Neurofibromatosis Type 1 (NF1)-Associated Inoperable Plexiform Neurofibromas (PNs) That Are Causing Significant MorbidityPlexiform Neurofibroma;Neurofibromatosis Type 1 (NF1)Drug: Mirdametinib (PD-0325901) oral capsule or dispersible tabletSpringWorks Therapeutics, Inc.NULLActive, not recruiting2 YearsN/AAll114Phase 2United States
3NCT02096471
(ClinicalTrials.gov)
June 201412/3/2014MEK Inhibitor PD-0325901 Trial in Adolescents and Adults With NF1A Phase 2 Trial of the MEK Inhibitor PD-0325901 in Adolescents and Adults With NF1-Associated Morbid Plexiform NeurofibromasNeurofibromatosis Type 1 and Growing or Symptomatic, Inoperable PNDrug: PD-0325901University of Alabama at BirminghamNULLCompleted16 YearsN/AAll19Phase 2United States